LL-37
ResearchLL-37 (Cathelicidin Antimicrobial Peptide)
- Category
- Immune & Inflammatory
- Aliases
- hCAP-18 fragment, Cathelicidin
- Administration
- Topical (research), Subcutaneous injection (research)
Timing
A general projection of what people report noticing over time, based on the known mechanism and reported use patterns. It is not a guarantee and individual experience varies considerably.
- 1
1–2 Weeks
For topical or wound-related use, some users report visibly faster healing within the first days to weeks.
- 2
3–4 Weeks
Continued use is commonly associated with reduced signs of local infection or irritation.
- 3
5–7 Weeks
Wound-related improvements, where present, tend to continue steadily through this period.
- 4
8–10 Weeks
Most acute, localized use cases resolve or plateau by this stage.
- 5
11–15 Weeks
Ongoing use beyond this point is less common outside of chronic wound research contexts.
- 6
16–20 Weeks
Long-term felt effects have not been well characterized in available research.
- 7
21–24 Weeks
This duration exceeds most typical use cases studied to date.
⚠️ Research context only. This is not medical advice and results are not guaranteed.